Medigen Vaccine Biologics Corp.
Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)(Medigen Vaccine Biologics Corp.)은 Melanoma Stage IV 표적 세포·유전자 치료로, Melanoma Stage IV 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 58건의 관련 임상이 등록되어 있습니다. 차별점: novel antimicrobial compounds are central focuses of medical research.
Melanoma Stage IV
Melanoma Stage IV
Active
oncolytic Newcastle disease virus LaSota strain and the chimeric cons
viral vectors, like lentivirus and vesicular stomatitis virus, we investigated the stability
novel antimicrobial compounds are central focuses of medical research
apoptosis, and suppressed cell migration, accompanied by a reduction in VEGFR-2 protein expression levels
EGFR-2 inhibition, follow
resistance to synthetic anthelmintics and concerns about their safety have driven the search for natural bioactive compounds with ant
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Medigen Vaccine Biologics Corp.
Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)(Medigen Vaccine Biologics Corp.)은 Melanoma Stage IV 표적 세포·유전자 치료로, Melanoma Stage IV 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 58건의 관련 임상이 등록되어 있습니다. 차별점: novel antimicrobial compounds are central focuses of medical research.
Melanoma Stage IV
Melanoma Stage IV
Active
oncolytic Newcastle disease virus LaSota strain and the chimeric cons
viral vectors, like lentivirus and vesicular stomatitis virus, we investigated the stability
novel antimicrobial compounds are central focuses of medical research
apoptosis, and suppressed cell migration, accompanied by a reduction in VEGFR-2 protein expression levels
EGFR-2 inhibition, follow
resistance to synthetic anthelmintics and concerns about their safety have driven the search for natural bioactive compounds with ant
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.